Rare & Orphan Lab · DeCure for X
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for brachydactyly type B1 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for brachydactyly type b1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
ROR family WNT receptor 2 (ROR2) — ROR2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 4GT4 · 2.406 Å · ligand none (apo structure). Experimental structure, not a prediction.
Brachydactyly type B1 is a congenital condition characterised by shortening of digits, and the abstracts provided contain no clinical trial or treatment data. A 1989 report described a family with features overlapping types A2 and D brachydactyly plus findings not previously noted, and proposed the term brachydactyly type A7 (Smorgasbord). A 1999 sibling pair with brachydactyly type B born to normal non-consanguineous parents was described, and the authors suggested that a subgroup with nail and distal phalanx involvement and distinct facies might be identical to Cooks syndrome. A 2020 case report of brachydactyly type A noted difficulty in classifying the subtype due to variable presentation.
No drug, no intervention, no survival or response rate is mentioned in any of these abstracts. The literature consists entirely of descriptive case reports and classification proposals. There is no evidence that any pharmacological agent has been tested for brachydactyly type B1.
What is missing is any clinical trial, any animal model of drug treatment, any molecular target identified for therapeutic intervention, and any funding directed toward repurposing or drug development for this condition. Patient stratification beyond the existing descriptive classification has not been attempted in a treatment context.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractWe report a family with a form of brachydactyly that involves characteristic features of types A2 and D brachydactyly plus features found in other types of brachydactyly and also features not previously noted. This set of findings represents a new syndrome, which we have termed brachydactyly type A7 (Smorgasbord).
https://doi.org/10.1111/j.1399-0004.1989.tb02940.xAbstractA sibling pair with brachydactyly type B born to a normal non-consanguineous couple are described and the severity of their condition discussed. It is proposed that a subgroup of individuals with brachydactyly type B principally involving the nails and distal phalanges, and also having distinct facies, might be identical to individuals having 'Cooks syndrome'.
https://doi.org/10.1097/00019605-199901000-00008AbstractBrachydactyly is a condition characterized by congenital shortening of digits or toes, which occurs due to short phalanges, metacarpal or metatarsal bones.[1] This condition may involve more than one digit or toe and depending on the involvement of the underlying bones and number of digits this condition, it is classified into five types (type A-type E).[2] They are inherited as autosomal dominant, recessive, or sporadic varieties. In this report, a rare case of Brachydactyly type A is presented, which had a variable presentation, causing difficulty in classifying the subtype.
https://doi.org/10.1055/s-0040-1714976Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
